Benjamin Solky, MD
MOHS-Micrographic Surgery · Boston, MANPI 1932186772
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 308 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations.
Across 308 payments — averaging $21.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- AbbVie$1K
- Novartis$591
- E.r. Squibb & Sons, L.L.C.$582
- Johnson & Johnson$544
- LEO Pharma Inc.$254
- plus $2K from 18 others
What the payments were for
- Food & beverage$6,503100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 54 | $1,200 |
| AbbVie | 67 | $1,144 |
| Novartis | 25 | $591 |
| E.r. Squibb & Sons, L.L.C. | 24 | $582 |
| Johnson & Johnson | 28 | $544 |
| LEO Pharma Inc. | 13 | $254 |
| Regeneron Healthcare Solutions, Inc. | 9 | $230 |
| Genentech USA, Inc. | 10 | $221 |
| Sun Pharmaceutical Industries Inc. | 10 | $218 |
| Bristol Myers Squibb | 10 | $215 |
| Arcutis Biotherapeutics, Inc. | 10 | $209 |
| UCB, Inc. | 8 | $178 |
| Incyte Corporation | 7 | $171 |
| Lilly USA, LLC | 7 | $152 |
| Organon | 5 | $141 |
| Sanofi | 5 | $136 |
| Galderma Laboratories, L.p. | 5 | $93 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 3 | $62 |
| Fresenius Kabi USA, LLC | 2 | $38 |
| Dermira, Inc. | 2 | $37 |
| Boehringer Ingelheim | 1 | $30 |
| Organogenesis Inc. | 1 | $25 |
| Pfizer | 1 | $19 |
| Almirall LLC | 1 | $14 |
How this compares
$6,503 in reported general payments places this provider in the 80th percentile of 38 mohs-micrographic surgery providers in Massachusetts.
See all mohs-micrographic surgery providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cephalexin | 567 | $3,328 |
| Fluorouracil | 16 | $826 |
| Clobetasol Propionate | 16 | $646 |
| Doxycycline Hyclate | 74 | $623 |
| Fluocinonide | 13 | $491 |
| Doxycycline Monohydrate | 53 | $465 |
| Triamcinolone Acetonide | 20 | $288 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Boston
- Sameer GuptaBoston$11K
- Jonathan WeissBoston$3K
- Paul MasseyBoston$1K
- Anna SutherlandBoston$657
- Katayun AdhamiBoston$560
- Ramone WilliamsBoston$200
- Nina RanBoston$121
- Patricia RicheyBoston$47
- Chrysalyne SchmultsJamaica Plain$58K
- Suzanne OlbrichtBurlington$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.